Answers are grounded in this paper and cite their sources.
Objective: Analyze seizure-free rates in studies of a new investigational AED, YKP3089. Background: Complete/near-complete seizure control may be needed for a new AED to achieve clinically meaningful improvements in quality of life in patients with refractory epilepsy. Despite development of ~20 new AEDs, the proportion of seizure-free patients in adjunctive treatment studies remains low. To help patients with refractory epilepsy, new AED development may need to use complete seizure control as an efficacy criterion. We report seizure-free rates in two double-blind placebo-controlled studies of patients with refractory partial-onset seizures in which YKP3089 was significantly more effective than Placebo in traditional primary endpoints (median [percnt] seizure reduction; ≥50[percnt] seizure reduction). Methods: Adults with ≥3 or 4 seizures/28 days during 8-wk baseline despite treatment with 1-3 AEDs were randomized to Placebo or YKP3089 (C013: 200 mg/day; C017: 100, 200, or 400 mg/day). 6-week titration phase followed by 6-week (C013) or 12-week (C017) maintenance phase. [percnt] patients seizure-free during the entire maintenance phase was determined. Results: In Study C013, 109 and 113 patients were randomized to Placebo and YKP3089, respectively, with 91[percnt] and 90[percnt] completing maintenance. Seizure-free rates were 9[percnt] with Placebo and 28[percnt] (<0.001) with YKP3089 200 mg. In Study C017, 108 patients were randomized to Placebo; 108, 110, and 111 were randomized to 100, 200, and 400 mg/day YKP3089, and 87[percnt], 88[percnt], 82[percnt], and 73[percnt], respectively, completed maintenance. YKP3089 100, 200, and 400 mg produced seizure-free rates of 3[percnt], 11[percnt] (p=0.004), and 20[percnt] (p<0.001), respectively, vs. 1[percnt] with Placebo. Most common AEs were dose related and included somnolence, dizziness, fatigue, diplopia, and gait disturbances. Conclusions: Treatment with YKP3089 was highly effective vs. Placebo in achieving seizure freedom. Further research must determine the durability of this outcome. Studies sponsored by SK Life Science, Inc.
No takes yet. Share an insight, caveat, or question.
Krauss et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: